Altered Binding Site Selection of p53 Transcription Cassettes by Hepatitis B Virus X Protein

Abstract

The key cellular regulator p53 is a common target of viral oncoproteins. However, the mechanism by which p53 transcription regulation is modulated by hepatitis B virus X protein (HBx), a transcription cofactor implicated in hepatitis B virus-associated hepatocellular carcinoma (HCC), is poorly understood. By integrating p53 chromatin immunoprecipitation (ChIP)-on-chip and expression profiling of an HBx-expressing cell culture system, we report that HBx alters p53 binding site selectivity in the regulatory regions of genes, and this is associated with their aberrant expression. Using an HBx-deregulated gene, p53AIP1, as a model, we show that HBx aberrantly increases p53AIP1 expression by conferring p53 selectivity for a more conserved binding site in its regulatory region. We further demonstrate that HBx-deregulated increased p53AIP1 expression is relevant in HCC livers and define a functional role for p53AIP1 in mediating HBx-induced apoptosis in vitro. Significantly, we provide evidence that specific p53-associated transcription cofactors and coregulators are differentially recruited in the presence of HBx, effecting a PCAF-mediated “p53 Lys320 acetylation switch” that results in altered binding site selection of distinct p53 transcription cassettes. The findings here clarify the role of HBx in modulating p53 transcription regulation and provide a novel mechanistic insight into this deregulation.

ACKNOWLEDGMENTS

This work was supported by a grant from the BioMedical Research Council (BMRC06/1/21/19/449), the National Medical Research Council (NMRC/1238/2009), and the Singapore Millennium Foundation, as well as block funding from the National Cancer Center, Singapore, and Duke-NUS Graduate Medical School to Caroline G. Lee.

We declare that we have no conflict of interest.